Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer.

Shi WL, Li J, Bao QL, Wu JN, Ge LP, Zhu LR, Wang Y, Zhu WF.

Med Oncol. 2014 Apr;31(4):893. doi: 10.1007/s12032-014-0893-8.

PMID:
24563335
2.

Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.

Wang S, Han X, Hu X, Wang X, Zhao L, Tang L, Feng Y, Wu D, Sun Y, Shi Y.

Clin Chim Acta. 2014 Mar 20;430:63-70. doi: 10.1016/j.cca.2013.12.026.

PMID:
24378285
3.

Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer.

Hu YM, Li J, Yu LC, Shi SB, Du YJ, Wu JN, Shi WL.

Pathol Oncol Res. 2015 Apr;21(2):257-65. doi: 10.1007/s12253-014-9816-4.

PMID:
24980156
4.

Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.

Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.

Exp Cell Res. 2014 May 1;323(2):288-96. doi: 10.1016/j.yexcr.2014.02.026.

PMID:
24631288
5.

Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.

Hsiao SH, Liu HE, Lee HL, Lin CL, Chen WY, Wu ZH, Lin SE, Chiang LL, Chung CL.

PLoS One. 2013 Dec 23;8(12):e83266. doi: 10.1371/journal.pone.0083266.

6.

[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].

Zhu X, Liang L, Liu C, Yin W, Chen S, Cao B.

Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):155-62. doi: 10.3779/j.issn.1009-3419.2014.02.15. Chinese.

7.

Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, Ohshimo S, Fujitaka K, Ohnishi H, Hamada H, Arihiro K, Kohno N.

Int J Cancer. 2008 Jun 1;122(11):2612-20. doi: 10.1002/ijc.23411.

9.

Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery.

Tang XP, Li J, Yu LC, Chen YC, Shi SB, Zhu LR, Chen P.

Lung Cancer. 2013 Aug;81(2):273-9. doi: 10.1016/j.lungcan.2013.05.005.

PMID:
23756092
10.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930.

PMID:
19414683
11.

Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.

Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K.

BMC Res Notes. 2013 Apr 8;6:139. doi: 10.1186/1756-0500-6-139.

12.

Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, Chou CL, Chen HC, Lin SM, Kuo HP.

Int J Cancer. 2012 Aug 1;131(3):E227-35. doi: 10.1002/ijc.27403.

13.

Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.

Zhao ZR, Wang JF, Lin YB, Wang F, Fu S, Zhang SL, Su XD, Jiang L, Zhang YG, Shao JY, Long H.

Med Oncol. 2014 Jan;31(1):810. doi: 10.1007/s12032-013-0810-6.

PMID:
24338271
14.

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.

Cancer. 2011 Jan 1;117(1):143-51. doi: 10.1002/cncr.25560.

15.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M.

J Natl Cancer Inst. 2005 May 4;97(9):643-55.

16.

M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma.

Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou W, Wang J, Yang B, Zhao Y, Rao Z, Gao J.

Med Oncol. 2014 Aug;31(8):127. doi: 10.1007/s12032-014-0127-0.

PMID:
25034365
17.

Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients.

Du YJ, Li J, Zhu WF, Wu Y, Tang XP, Wang Y, Hu YM.

Tumour Biol. 2014 May;35(5):4499-507. doi: 10.1007/s13277-013-1592-3.

PMID:
24390669
18.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Review.

PMID:
21435938
19.

Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.

Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, Linn SC.

J Thorac Oncol. 2010 Dec;5(12):1939-48. doi: 10.1097/JTO.0b013e3181f77a39.

20.

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.

Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A.

Lung Cancer. 2010 Mar;67(3):355-60. doi: 10.1016/j.lungcan.2009.04.021.

PMID:
19473722
Items per page

Supplemental Content

Support Center